Eli Lilly Gains FDA Approval for Weekly Insulin Onswik

The US Food and Drug Administration has approved Eli Lilly’s once-weekly basal insulin, named Onswik, specifically for individuals with type 2 diabetes. This new product is designed to minimize the number of insulin injections patients need to take each week, potentially enhancing the convenience of insulin administration.

The FDA's approval comes after thorough clinical testing of the medication. Eli Lilly is currently preparing Onswik for the US market, and healthcare providers will assess its suitability for individual patients.

This approval introduces another treatment option for those requiring basal insulin, reflecting Eli Lilly's commitment to improving diabetes management.